Abstract
Background: Use of recombinant follicle stimulating hormone (rFSH) in a cartridge pen device offers obvious benefits for donor oocyte cycles including the administration of fewer and more patient-friendly injectable medications. Methods: In a University-based IVF program, a total of 98 oocyte donor cycles using rFSH either reconstituted or as a pen device given to 118 recipients (eight split cycles) were retrospectively reviewed. Following discontinuation of oral contraceptive, controlled ovarian hyperstimulation was begun using either reconstituted rFSH (n = 19) or rFSH with a cartridge pen device (n = 79) (150-300IU qd). GnRH-antagonists (Ganirelix, Organon) and an additional 75 IU of rFSH/day were begun when lead follicles were 13-14 mm in greatest diameter. The primary endpoints analyzed included cycle stimulation characteristics for each donor group and donor medication tolerance assessment with respect to each rFSH formulation, while secondary outcome measures included clinical pregnancy and implantation rates. Results: Oocyte donors using the pen required significantly less rFSH (2734 IU vs. 3276 IU, p <0.05) and scored significantly higher medication tolerance scores (3.9 ± 0.4 vs. 3.1 ± 0.6, p <0.05). No other differences in cycle stimulation for oocyte donors and clinical outcomes for recipients were seen including pregnancy rates (pen, 77% vs. reconstituted, 55%, p - NS) and clinical pregnancy rates (61 % vs. 45%, p - NS). However, significantly greater implantation rates (57% vs. 31%, p <0.01) occurred in the pen group. Conclusion: Compared to reconstituted formulations, the pen device results in lower gonadotropin requirements and provides a simplified dosing method with better tolerance.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 865-870 |
| Number of pages | 6 |
| Journal | Current Medical Research and Opinion |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2007 |
Fingerprint
Keywords
- Cartridge pen device
- GnRH-antagonists
- IVF-ET
- Oocyte donation
- rFSH
ASJC Scopus subject areas
- Medicine(all)
Cite this
A retrospective comparison of clinical outcomes and satisfaction using reconstituted recombinant gonadotropins (rFSH) or cartridge rFSH with a pen device in donor oocyte cycles. / Christianson, Mindy Sue; Barker, M. A.; Schouweiler, C.; Lindheim, Steven R.
In: Current Medical Research and Opinion, Vol. 23, No. 4, 04.2007, p. 865-870.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A retrospective comparison of clinical outcomes and satisfaction using reconstituted recombinant gonadotropins (rFSH) or cartridge rFSH with a pen device in donor oocyte cycles
AU - Christianson, Mindy Sue
AU - Barker, M. A.
AU - Schouweiler, C.
AU - Lindheim, Steven R.
PY - 2007/4
Y1 - 2007/4
N2 - Background: Use of recombinant follicle stimulating hormone (rFSH) in a cartridge pen device offers obvious benefits for donor oocyte cycles including the administration of fewer and more patient-friendly injectable medications. Methods: In a University-based IVF program, a total of 98 oocyte donor cycles using rFSH either reconstituted or as a pen device given to 118 recipients (eight split cycles) were retrospectively reviewed. Following discontinuation of oral contraceptive, controlled ovarian hyperstimulation was begun using either reconstituted rFSH (n = 19) or rFSH with a cartridge pen device (n = 79) (150-300IU qd). GnRH-antagonists (Ganirelix, Organon) and an additional 75 IU of rFSH/day were begun when lead follicles were 13-14 mm in greatest diameter. The primary endpoints analyzed included cycle stimulation characteristics for each donor group and donor medication tolerance assessment with respect to each rFSH formulation, while secondary outcome measures included clinical pregnancy and implantation rates. Results: Oocyte donors using the pen required significantly less rFSH (2734 IU vs. 3276 IU, p <0.05) and scored significantly higher medication tolerance scores (3.9 ± 0.4 vs. 3.1 ± 0.6, p <0.05). No other differences in cycle stimulation for oocyte donors and clinical outcomes for recipients were seen including pregnancy rates (pen, 77% vs. reconstituted, 55%, p - NS) and clinical pregnancy rates (61 % vs. 45%, p - NS). However, significantly greater implantation rates (57% vs. 31%, p <0.01) occurred in the pen group. Conclusion: Compared to reconstituted formulations, the pen device results in lower gonadotropin requirements and provides a simplified dosing method with better tolerance.
AB - Background: Use of recombinant follicle stimulating hormone (rFSH) in a cartridge pen device offers obvious benefits for donor oocyte cycles including the administration of fewer and more patient-friendly injectable medications. Methods: In a University-based IVF program, a total of 98 oocyte donor cycles using rFSH either reconstituted or as a pen device given to 118 recipients (eight split cycles) were retrospectively reviewed. Following discontinuation of oral contraceptive, controlled ovarian hyperstimulation was begun using either reconstituted rFSH (n = 19) or rFSH with a cartridge pen device (n = 79) (150-300IU qd). GnRH-antagonists (Ganirelix, Organon) and an additional 75 IU of rFSH/day were begun when lead follicles were 13-14 mm in greatest diameter. The primary endpoints analyzed included cycle stimulation characteristics for each donor group and donor medication tolerance assessment with respect to each rFSH formulation, while secondary outcome measures included clinical pregnancy and implantation rates. Results: Oocyte donors using the pen required significantly less rFSH (2734 IU vs. 3276 IU, p <0.05) and scored significantly higher medication tolerance scores (3.9 ± 0.4 vs. 3.1 ± 0.6, p <0.05). No other differences in cycle stimulation for oocyte donors and clinical outcomes for recipients were seen including pregnancy rates (pen, 77% vs. reconstituted, 55%, p - NS) and clinical pregnancy rates (61 % vs. 45%, p - NS). However, significantly greater implantation rates (57% vs. 31%, p <0.01) occurred in the pen group. Conclusion: Compared to reconstituted formulations, the pen device results in lower gonadotropin requirements and provides a simplified dosing method with better tolerance.
KW - Cartridge pen device
KW - GnRH-antagonists
KW - IVF-ET
KW - Oocyte donation
KW - rFSH
UR - http://www.scopus.com/inward/record.url?scp=34247327712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247327712&partnerID=8YFLogxK
U2 - 10.1185/030079907X178784
DO - 10.1185/030079907X178784
M3 - Article
C2 - 17407643
AN - SCOPUS:34247327712
VL - 23
SP - 865
EP - 870
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 4
ER -